Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent versus continuous panitumumab plus FOLFIRI in first-line RAS/B-RAF wild-type metastatic colorectal cancer
2017-003628-65Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab, irinotecan, levoleucovorin and fluorouracil in colorectal adenocarcinoma (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Progression-free survival on treatment. Started Oct 2020; status: completed.
02
Drugs
panitumumabirinotecanlevoleucovorinfluorouracil
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2017-003628-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003628-65.